Insmed, Inc. (INSM) – What Are Investment Firms Saying About This Stock?

Shares of Insmed, Inc. (NASDAQ:INSM) have been assigned a consensus rating of “Moderate Buy” from the twenty-five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twenty-two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $198.91.

Several analysts have recently issued reports on INSM shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Thursday, October 15th. Raymond James Financial set a $173.00 target price on Insmed in a research note on Tuesday, October 20th. BMO Capital Markets reissued an “outperform” rating on shares of Insmed in a research note on Tuesday, October 6th. Jefferies Financial Group restated a “buy” rating and set a $175.00 price target on shares of Insmed in a report on Thursday, August 6th. Finally, Morgan Stanley reduced their price target on Insmed from $218.00 to $213.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 21st.

Insmed Stock Down 0.1%

Shares of INSM opened at $93.33 on Tuesday. Insmed has a fifty-two week low of $90.39 and a fifty-two week high of $212.75. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. The firm’s 50 day moving average price is $114.59 and its 200 day moving average price is $127.06.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The firm’s revenue was up 296.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.70) EPS. As a group, analysts predict that Insmed will post -1.60 EPS for the current fiscal year.

Insider Activity

In related news, COO Roger Adsett sold 239,850 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer directly owned 98,744 shares in the company, valued at approximately $13,159,612.88. This represents a 70.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David R. Brennan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares in the company, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in INSM. Sei Investments Co. increased its position in shares of Insmed by 56.8% in the 1st quarter. Sei Investments Co. now owns 1,395,794 shares of the biopharmaceutical company’s stock valued at $228,239,000 after purchasing an additional 505,624 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Insmed by 14.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 1,102,248 shares of the biopharmaceutical company’s stock worth $178,659,000 after purchasing an additional 143,285 shares during the last quarter. NWI Management LP lifted its position in shares of Insmed by 2.6% during the 1st quarter. NWI Management LP now owns 1,014,000 shares of the biopharmaceutical company’s stock worth $165,809,000 after purchasing an additional 25,540 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Insmed by 18.8% during the 1st quarter. Principal Financial Group Inc. now owns 916,464 shares of the biopharmaceutical company’s stock worth $149,860,000 after purchasing an additional 145,106 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Insmed by 480.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,266,788 shares of the biopharmaceutical company’s stock worth $144,591,000 after purchasing an additional 1,048,518 shares during the last quarter.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases. The company concentrates on conditions with significant unmet medical needs, particularly in pulmonary and infectious diseases.

Insmed’s lead commercial product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibacterial therapy used in the United States for adults with refractory Mycobacterium avium complex lung disease as part of a combination antibacterial regimen.